JP2014511893A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014511893A5 JP2014511893A5 JP2014505613A JP2014505613A JP2014511893A5 JP 2014511893 A5 JP2014511893 A5 JP 2014511893A5 JP 2014505613 A JP2014505613 A JP 2014505613A JP 2014505613 A JP2014505613 A JP 2014505613A JP 2014511893 A5 JP2014511893 A5 JP 2014511893A5
- Authority
- JP
- Japan
- Prior art keywords
- methyloxy
- imidazo
- compound
- ethyl
- dimethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 11
- -1 3,5-Dimethyl-4-isoxazolyl Chemical group 0.000 claims 6
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- GCMNJUJAKQGROZ-UHFFFAOYSA-N 1,2-Dihydroquinolin-2-imine Chemical compound C1=CC=CC2=NC(N)=CC=C21 GCMNJUJAKQGROZ-UHFFFAOYSA-N 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 229940125763 bromodomain inhibitor Drugs 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- IRFHMTUHTBSEBK-QGZVFWFLSA-N tert-butyl n-[(2s)-2-(2,5-difluorophenyl)-3-quinolin-3-ylpropyl]carbamate Chemical compound C1([C@H](CC=2C=C3C=CC=CC3=NC=2)CNC(=O)OC(C)(C)C)=CC(F)=CC=C1F IRFHMTUHTBSEBK-QGZVFWFLSA-N 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- FIVLGTQJUXPVRU-UHFFFAOYSA-N 2-[[7-(3,5-dimethyl-1,2-oxazol-4-yl)-8-methoxy-1-(oxan-4-ylmethyl)imidazo[4,5-c]quinolin-2-yl]amino]ethanol Chemical compound OCCNC1=NC2=CN=C3C=C(C4=C(ON=C4C)C)C(OC)=CC3=C2N1CC1CCOCC1 FIVLGTQJUXPVRU-UHFFFAOYSA-N 0.000 claims 1
- HHQIOVSKCYEFDZ-MRXNPFEDSA-N 2-[[7-(3,5-dimethyl-1,2-oxazol-4-yl)-8-methoxy-1-[(1r)-1-phenylethyl]imidazo[4,5-c]quinolin-2-yl]amino]ethanol Chemical compound C1([C@@H](C)N2C3=C4C=C(C(=CC4=NC=C3N=C2NCCO)C2=C(ON=C2C)C)OC)=CC=CC=C1 HHQIOVSKCYEFDZ-MRXNPFEDSA-N 0.000 claims 1
- KBQLRXYOFJFCCX-UHFFFAOYSA-N 4-[7-(3,5-dimethyl-1,2-oxazol-4-yl)-8-methoxy-1-(oxan-4-ylmethyl)imidazo[4,5-c]quinolin-2-yl]morpholine Chemical compound C1COCCN1C1=NC2=CN=C3C=C(C4=C(ON=C4C)C)C(OC)=CC3=C2N1CC1CCOCC1 KBQLRXYOFJFCCX-UHFFFAOYSA-N 0.000 claims 1
- UEUCJJAVDZDKPJ-GOSISDBHSA-N 4-[7-(3,5-dimethyl-1,2-oxazol-4-yl)-8-methoxy-1-[(1r)-1-phenylethyl]imidazo[4,5-c]quinolin-2-yl]morpholine Chemical compound C1([C@@H](C)N2C3=C4C=C(C(=CC4=NC=C3N=C2N2CCOCC2)C2=C(ON=C2C)C)OC)=CC=CC=C1 UEUCJJAVDZDKPJ-GOSISDBHSA-N 0.000 claims 1
- GPBXKDORLRYAFV-LJQANCHMSA-N 4-[8-methoxy-1-[(1r)-1-phenylethyl]-2-piperidin-1-ylimidazo[4,5-c]quinolin-7-yl]-3,5-dimethyl-1,2-oxazole Chemical compound C1([C@@H](C)N2C3=C4C=C(C(=CC4=NC=C3N=C2N2CCCCC2)C2=C(ON=C2C)C)OC)=CC=CC=C1 GPBXKDORLRYAFV-LJQANCHMSA-N 0.000 claims 1
- NZVLCCBRSYNMIZ-UHFFFAOYSA-N 7-(3,5-dimethyl-1,2-oxazol-4-yl)-8-methoxy-1-(1-methoxypropan-2-yl)-n-(2-morpholin-4-ylethyl)imidazo[4,5-c]quinolin-2-amine Chemical compound N=1C2=CN=C3C=C(C4=C(ON=C4C)C)C(OC)=CC3=C2N(C(C)COC)C=1NCCN1CCOCC1 NZVLCCBRSYNMIZ-UHFFFAOYSA-N 0.000 claims 1
- IRVWWBFBBFEZOT-UHFFFAOYSA-N 7-(3,5-dimethyl-1,2-oxazol-4-yl)-8-methoxy-1-(oxan-4-ylmethyl)imidazo[4,5-c]quinolin-2-amine Chemical compound NC1=NC2=CN=C3C=C(C4=C(ON=C4C)C)C(OC)=CC3=C2N1CC1CCOCC1 IRVWWBFBBFEZOT-UHFFFAOYSA-N 0.000 claims 1
- AEXWAWHGUXRIOO-UHFFFAOYSA-N 7-(3,5-dimethyl-1,2-oxazol-4-yl)-8-methoxy-1-(pyridin-2-ylmethyl)imidazo[4,5-c]quinolin-2-amine Chemical compound NC1=NC2=CN=C3C=C(C4=C(ON=C4C)C)C(OC)=CC3=C2N1CC1=CC=CC=N1 AEXWAWHGUXRIOO-UHFFFAOYSA-N 0.000 claims 1
- HCEZPGCCFZDDQO-UHFFFAOYSA-N 7-(3,5-dimethyl-1,2-oxazol-4-yl)-8-methoxy-n,n-dimethyl-1-(oxan-4-ylmethyl)imidazo[4,5-c]quinolin-2-amine Chemical compound CN(C)C1=NC2=CN=C3C=C(C4=C(ON=C4C)C)C(OC)=CC3=C2N1CC1CCOCC1 HCEZPGCCFZDDQO-UHFFFAOYSA-N 0.000 claims 1
- RWOFLHZRPGAHPW-UHFFFAOYSA-N 7-(3,5-dimethyl-1,2-oxazol-4-yl)-8-methoxy-n-(2-methoxyethyl)-1-(1-methoxypropan-2-yl)imidazo[4,5-c]quinolin-2-amine Chemical compound COC1=CC2=C3N(C(C)COC)C(NCCOC)=NC3=CN=C2C=C1C=1C(C)=NOC=1C RWOFLHZRPGAHPW-UHFFFAOYSA-N 0.000 claims 1
- NDOYCNITPWYWHM-UHFFFAOYSA-N 7-(3,5-dimethyl-1,2-oxazol-4-yl)-8-methoxy-n-(2-methoxyethyl)-1-(oxan-4-ylmethyl)imidazo[4,5-c]quinolin-2-amine Chemical compound COC1=CC2=C3N(CC4CCOCC4)C(NCCOC)=NC3=CN=C2C=C1C=1C(C)=NOC=1C NDOYCNITPWYWHM-UHFFFAOYSA-N 0.000 claims 1
- VNTLEGVQLWKYEU-MRXNPFEDSA-N 7-(3,5-dimethyl-1,2-oxazol-4-yl)-8-methoxy-n-(2-methoxyethyl)-1-[(1r)-1-pyridin-2-ylethyl]imidazo[4,5-c]quinolin-2-amine Chemical compound COC1=CC2=C3N([C@H](C)C=4N=CC=CC=4)C(NCCOC)=NC3=CN=C2C=C1C=1C(C)=NOC=1C VNTLEGVQLWKYEU-MRXNPFEDSA-N 0.000 claims 1
- XYYDBYHXTRBXDP-UHFFFAOYSA-N 7-(3,5-dimethyl-1,2-oxazol-4-yl)-8-methoxy-n-(2-morpholin-4-ylethyl)-1-(oxan-4-ylmethyl)imidazo[4,5-c]quinolin-2-amine Chemical compound C1COCCN1CCNC1=NC2=CN=C3C=C(C4=C(ON=C4C)C)C(OC)=CC3=C2N1CC1CCOCC1 XYYDBYHXTRBXDP-UHFFFAOYSA-N 0.000 claims 1
- VVNHPRQSIABGMX-UHFFFAOYSA-N 7-(3,5-dimethyl-1,2-oxazol-4-yl)-n-ethyl-8-methoxy-1-(oxan-4-ylmethyl)imidazo[4,5-c]quinolin-2-amine Chemical compound COC1=CC2=C3N(CC4CCOCC4)C(NCC)=NC3=CN=C2C=C1C=1C(C)=NOC=1C VVNHPRQSIABGMX-UHFFFAOYSA-N 0.000 claims 1
- IKTBLXAKAQPULU-UHFFFAOYSA-N 7-(3,5-dimethyl-1,2-oxazol-4-yl)-n-ethyl-8-methoxy-1-[1-(1-methylpyrazol-4-yl)ethyl]imidazo[4,5-c]quinolin-2-amine Chemical compound COC1=CC2=C3N(C(C)C4=CN(C)N=C4)C(NCC)=NC3=CN=C2C=C1C=1C(C)=NOC=1C IKTBLXAKAQPULU-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- OGTYKUGNAVOMRH-UHFFFAOYSA-N n'-[7-(3,5-dimethyl-1,2-oxazol-4-yl)-8-methoxy-1-(1-methoxypropan-2-yl)imidazo[4,5-c]quinolin-2-yl]ethane-1,2-diamine Chemical compound COC1=CC2=C3N(C(C)COC)C(NCCN)=NC3=CN=C2C=C1C=1C(C)=NOC=1C OGTYKUGNAVOMRH-UHFFFAOYSA-N 0.000 claims 1
- OSDROQOFDHWYKD-UHFFFAOYSA-N n'-[7-(3,5-dimethyl-1,2-oxazol-4-yl)-8-methoxy-1-(oxan-4-ylmethyl)imidazo[4,5-c]quinolin-2-yl]ethane-1,2-diamine Chemical compound NCCNC1=NC2=CN=C3C=C(C4=C(ON=C4C)C)C(OC)=CC3=C2N1CC1CCOCC1 OSDROQOFDHWYKD-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1106799.8A GB201106799D0 (en) | 2011-04-21 | 2011-04-21 | Novel compounds |
| GB1106799.8 | 2011-04-21 | ||
| PCT/EP2012/057114 WO2012143416A2 (en) | 2011-04-21 | 2012-04-19 | Novel compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014511893A JP2014511893A (ja) | 2014-05-19 |
| JP2014511893A5 true JP2014511893A5 (enExample) | 2015-04-30 |
| JP5856673B2 JP5856673B2 (ja) | 2016-02-10 |
Family
ID=44147382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014505613A Expired - Fee Related JP5856673B2 (ja) | 2011-04-21 | 2012-04-19 | ７−（３，５−ジメチル−４−イソオキサゾリル）−８−（メチルオキシ）−１Ｈ−イミダゾ［４，５−ｃ］キノリン誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8846709B2 (enExample) |
| EP (1) | EP2699573B1 (enExample) |
| JP (1) | JP5856673B2 (enExample) |
| ES (1) | ES2637595T3 (enExample) |
| GB (1) | GB201106799D0 (enExample) |
| WO (1) | WO2012143416A2 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201114103D0 (en) * | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| AU2013365926B9 (en) | 2012-12-21 | 2019-01-17 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
| AU2014249034A1 (en) | 2013-03-11 | 2015-09-24 | Abbvie Inc. | Fused tetracyclic bromodomain inhibitors |
| AU2014249025A1 (en) | 2013-03-11 | 2015-09-17 | Abbvie Inc. | Bromodomain inhibitors |
| BR112015022417A2 (pt) | 2013-03-14 | 2017-07-18 | Convergene Llc | métodos e composições para inibição de proteínas contendo bromodomínio |
| SG11201506924YA (en) | 2013-03-15 | 2015-09-29 | Incyte Corp | Tricyclic heterocycles as bet protein inhibitors |
| TWI527811B (zh) * | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| SI3010503T1 (sl) | 2013-06-21 | 2020-07-31 | Zenith Epigenetics Ltd. | Novi biciklični inhibitorji bromodomene |
| CN105492439B (zh) | 2013-06-21 | 2019-11-22 | 齐尼思表观遗传学有限公司 | 作为溴结构域抑制剂的取代的双环化合物 |
| AR096837A1 (es) | 2013-07-08 | 2016-02-03 | Incyte Corp | Heterociclos tricíclicos como inhibidores de proteínas bet |
| EP3024327B1 (en) * | 2013-07-25 | 2019-09-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
| WO2015015318A2 (en) | 2013-07-31 | 2015-02-05 | Zenith Epigenetics Corp. | Novel quinazolinones as bromodomain inhibitors |
| WO2015049629A1 (en) * | 2013-10-01 | 2015-04-09 | Piramal Enterprises Limited | Imidazoquinoline compounds as bromodomain inhibitors |
| AU2013406206B2 (en) * | 2013-11-26 | 2017-07-20 | Gilead Sciences, Inc. | Quinoline derivatives as bromodomain inhibitors |
| WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| UA119870C2 (uk) | 2014-04-23 | 2019-08-27 | Інсайт Корпорейшн | 1H-ПІРОЛО[2,3-c]ПІРИДИН-7(6H)-ОНИ ТА ПІРАЗОЛО[3,4-c]ПІРИДИН-7(6H)-ОНИ ЯК ІНГІБІТОРИ БІЛКІВ BET |
| US9527864B2 (en) | 2014-09-15 | 2016-12-27 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| EP3227281A4 (en) | 2014-12-01 | 2018-05-30 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| HK1246273B (en) | 2014-12-01 | 2019-12-06 | 恒翼生物医药(上海)股份有限公司 | Substituted pyridines as bromodomain inhibitors |
| US10292968B2 (en) | 2014-12-11 | 2019-05-21 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
| CA2966450A1 (en) | 2014-12-17 | 2016-06-23 | Olesya KHARENKO | Inhibitors of bromodomains |
| EP3253756B1 (en) * | 2015-02-03 | 2021-09-22 | Trillium Therapeutics Inc. | Fluorinated imidazo[4,5-c]quinoline derivatives as inhibitors of bromodomain containing proteins |
| GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
| WO2016186453A1 (en) * | 2015-05-20 | 2016-11-24 | Kainos Medicine, Inc. | Quinoline derivatives as bromodomain inhibitors |
| AU2016276963C1 (en) | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| WO2016203335A1 (en) | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors |
| CA2996977A1 (en) | 2015-09-11 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Acetamide thienotriazolodiazepines and uses thereof |
| BR112018004618A2 (pt) | 2015-09-11 | 2018-09-25 | Dana-Farber Cancer Institute, Inc. | ciano tienotriazoldiazepinas e usos das mesmas |
| TW201722966A (zh) | 2015-10-29 | 2017-07-01 | 英塞特公司 | Bet蛋白質抑制劑之非晶固體形式 |
| US10913752B2 (en) | 2015-11-25 | 2021-02-09 | Dana-Farber Cancer Institute, Inc. | Bivalent bromodomain inhibitors and uses thereof |
| EP4050005B1 (en) | 2015-11-25 | 2024-12-25 | Convergene Llc | Bicyclic bet bromodomain inhibitors and uses thereof |
| IL263824B2 (en) | 2016-06-20 | 2023-10-01 | Incyte Corp | Crystals in solid form in the presence of an inhibitor |
| WO2018196662A1 (zh) * | 2017-04-28 | 2018-11-01 | 四川科伦博泰生物医药股份有限公司 | 包含苯并二氮䓬类化合物的注射用组合物及其制备方法 |
| US12497395B2 (en) | 2019-04-24 | 2025-12-16 | Convergene, Llc | Small molecule bromodomain inhibitors and uses therof |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| EP1590348A1 (en) * | 2002-12-20 | 2005-11-02 | 3M Innovative Properties Company | Aryl / hetaryl substituted imidazoquinolines |
| JP4641526B2 (ja) | 2003-11-03 | 2011-03-02 | グラクソ グループ リミテッド | 流体分配デバイス |
| MX2008007864A (es) * | 2005-12-16 | 2009-03-04 | Coley Pharm Group Inc | Imidazoquinolinas, imidazonaftiridinas, e imidazopiridinas sustituidas, composiciones y metodos. |
| JP2008156311A (ja) | 2006-12-26 | 2008-07-10 | Institute Of Physical & Chemical Research | Ｂｒｄ２ブロモドメイン結合剤 |
| EP2239264A4 (en) | 2007-12-28 | 2012-01-11 | Mitsubishi Tanabe Pharma Corp | ANTITUMORAL MEDIUM |
-
2011
- 2011-04-21 GB GBGB1106799.8A patent/GB201106799D0/en not_active Ceased
-
2012
- 2012-04-19 JP JP2014505613A patent/JP5856673B2/ja not_active Expired - Fee Related
- 2012-04-19 WO PCT/EP2012/057114 patent/WO2012143416A2/en not_active Ceased
- 2012-04-19 US US14/111,783 patent/US8846709B2/en not_active Expired - Fee Related
- 2012-04-19 ES ES12716379.8T patent/ES2637595T3/es active Active
- 2012-04-19 EP EP12716379.8A patent/EP2699573B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014511893A5 (enExample) | ||
| JP2013510120A5 (enExample) | ||
| JP2014513110A5 (enExample) | ||
| HRP20161674T1 (hr) | 4-(8-METOKSI-1-((1-METOKSIPROPAN-2-IL)-2-(TETRAHIDRO-2H-PIRAN-4-IL)-1H-IMIDAZO[4,5-c]KINOLIN-7-IL)-3,5-DIMETILIZOKSAZOL I NJEGOVA UPOTREBA KAO INHIBITORA BROMODOMENE | |
| JP2013510124A5 (enExample) | ||
| JP2014521735A5 (enExample) | ||
| JP2014505735A5 (enExample) | ||
| JP2012512158A5 (enExample) | ||
| JP2013512903A5 (enExample) | ||
| JP2012500277A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP6441219B2 (ja) | ｍＴＯＲ経路関連疾患を治療するための化合物 | |
| JP2013542261A5 (enExample) | ||
| EA201650029A1 (ru) | Пиразолопиридины и пиразолопиримидины | |
| HRP20120918T1 (hr) | Aminopirazolski spoj | |
| JP2015537020A5 (enExample) | ||
| JP2017502068A5 (enExample) | ||
| JP2013529611A5 (enExample) | ||
| JP2016501221A5 (enExample) | ||
| JP2013540713A5 (enExample) | ||
| EA201390823A1 (ru) | ДВОЙНЫЕ ИНГИБИТОРЫ PI3 КИНАЗЫ/mTOR | |
| JP2017504635A5 (enExample) | ||
| JP2016516074A5 (enExample) | ||
| JP2014500861A5 (enExample) | ||
| JP2019518079A5 (enExample) |